News Brent Saunders ejects from Bausch + Lomb once again Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.
News Bausch + Lomb drug fails in glaucoma, but a new use beckons Bausch + Lomb has had a hole blown in its pharma pipeline, after disappointing trial results forced it to abandon BL117 for glaucoma.
News Bausch + Lomb dips on rumour of failing takeover talks Private equity group Blackstone is reported to be thinking of pulling out of a consortium to buy ophthalmology specialist Bausch + Lomb.
News Bausch + Lomb buys US rights to Stada's Lucentis biosimilar Bausch + Lomb has bought US and Canadian rights to a potential biosimilar competitor to Novartis’ Lucentis from Germany’s Stada, as the blockbuster approaches the end of its patent protecte
News Aspen, Bambusa close IPOs as Corxel takes SPAC route Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
